AORT Stock Analysis: Artivion | NYSE
Medical Devices | NYSE, USA | Market Cap: 1.138m USD | 12M Return: -43.7% | US2289031005 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 15.5M
Qual. Beats: 0
Rev. Trend: 98.5%
Qual. Beats: 1
Warnings
Tailwinds
No distinct edge detected
Seasonality 11.7 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Artivion, Inc. is a U.S.-based medical device company that manufactures, processes, and distributes implantable medical devices and human tissues for cardiac and vascular surgery customers worldwide. The company operates within the Health Care Equipment sub-industry, addressing niches in heart valve replacement, aortic disease treatment, and surgical sealing and tissue preservation.
Its product portfolio spans mechanical and tissue heart valves (including the On-X line and CryoValve SG pulmonary valve), a broad family of stent graft systems for aortic and peripheral vascular procedures (E-vita, E-nside, E-tegra, NEXUS, and others), surgical sealants (BioGlue), and decellularized tissue and patch products (SynerGraft, PhotoFix). The business is typically categorized as a specialty medical device and tissue-engineering company, combining capital-implant sales with recurring tissue-preservation services.
Artivion sells primarily through a direct sales force targeting physicians, hospitals, and other healthcare facilities. The company was incorporated in 1984 as CryoLife, Inc., is headquartered in Kennesaw, Georgia, and adopted its current name in January 2022.
- AMDS and NEXUS stent graft systems drive aortic segment revenue growth
- On-X heart valve and BioGlue sealant sales anchor recurring device revenue
- FDA and CE Mark approvals accelerate new aortic repair product launches
| Net Income: -3.17m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.01 > 0.02 and ΔFCF/TA -1.93 > 1.0 |
| NWC/Revenue: 56.09% < 20% (prev 62.25%; Δ -6.16% < -1%) |
| CFO/TA 0.04 > 3% & CFO 40.0m > Net Income -3.17m |
| Net Debt (375.2m) to EBITDA (57.4m): 6.54 < 3 |
| Current Ratio: 3.47 > 1.5 & < 3 |
| Outstanding Shares: last quarter (48.5m) vs 12m ago 6.97% < -2% |
| Gross Margin: 62.80% > 18% (prev 63.99%; Δ -1.19% > 0.5%) |
| Asset Turnover: 49.36% > 50% (prev 48.31%; Δ 1.05% > 0%) |
| Interest Coverage Ratio: 1.09 > 6 (EBIT TTM 26.5m / Interest Expense TTM 24.3m) |
| A: 0.25 (Total Current Assets 371.4m - Total Current Liabilities 106.9m) / Total Assets 1.07b |
| B: -0.06 (Retained Earnings -63.6m / Total Assets 1.07b) |
| C: 0.03 (EBIT TTM 26.5m / Avg Total Assets 955.2m) |
| D: 0.71 (Book Value of Equity 445.6m / Total Liabilities 626.3m) |
| Altman-Z'' = 2.36 = BBB |
| DSRI: 0.94 (Receivables 110.8m/101.2m, Revenue 471.5m/405.0m) |
| GMI: 1.02 (GM 63.99% / 62.80%) |
| AQI: 1.05 (AQ_t 0.55 / AQ_t-1 0.52) |
| SGI: 1.16 (Revenue 471.5m / 405.0m) |
| TATA: -0.04 (NI -3.17m - CFO 40.0m) / TA 1.07b) |
| Beneish M = -2.92 (Cap -4..+1) = A |
As of September 25, 2026, the stock is trading at USD 23.03 with a total of 567,199 shares traded. Over the past week, the price has changed by -3.56%, over one month by -14.35%, over three months by +4.54% and over the past year by -43.71%.
Current recommended Stop Loss: 20.90 (which is 9.2% or 2 ATR below the current price).
Artivion has received a consensus analysts rating of 4.67. Therefore, it is recommended to buy AORT.
- StrongBuy: 4
- Buy: 2
- Hold: 0
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 42.2 | 83% |
P/E Forward = 35.0877
P/S = 2.4147
P/B = 2.555
P/EG = 181.5
Revenue TTM = 471.5m USD
EBIT TTM = 26.5m USD
EBITDA TTM = 57.4m USD
Long Term Debt = 363.4m USD (from longTermDebt, last quarter)
Short Term Debt = 5.92m USD (from shortTermDebt, last quarter)
Debt = 452.5m USD (from shortLongTermDebtTotal, last quarter) + Leases 44.5m
Net Debt = 375.2m USD (calculated: Debt 452.5m - CCE 77.3m)
Enterprise Value = 1.51b USD (1.14b + Debt 452.5m - CCE 77.3m)
Interest Coverage Ratio = 1.09 (Ebit TTM 26.5m / Interest Expense TTM 24.3m)
EV/FCF = -138.8x (Enterprise Value 1.51b / FCF TTM -10.9m)
FCF Yield = -0.72% (FCF TTM -10.9m / Enterprise Value 1.51b)
FCF Margin = -2.31% (FCF TTM -10.9m / Revenue TTM 471.5m)
Net Margin = -0.67% (Net Income TTM -3.17m / Revenue TTM 471.5m)
Gross Margin = 62.80% ((Revenue TTM 471.5m - Cost of Revenue TTM 175.4m) / Revenue TTM)
Gross Margin QoQ = 64.03% (prev 61.49%)
Tobins Q-Ratio = 1.41 (Enterprise Value 1.51b / Total Assets 1.07b)
Interest Expense / Debt = 5.36% (Interest Expense 24.3m / Debt 452.5m)
Taxrate = 33.91% (5.01m / 14.8m)
NOPAT = 17.5m (EBIT 26.5m * (1 - 33.91%))
Current Ratio = 3.47 (Total Current Assets 371.4m / Total Current Liabilities 106.9m)
Debt / Equity = 1.02 (Debt 452.5m / totalStockholderEquity, last quarter 445.6m)
Debt / EBITDA = 6.54 (Net Debt 375.2m / EBITDA 57.4m)
Debt / FCF = -34.40 (negative FCF - burning cash) (Net Debt 375.2m / FCF TTM -10.9m)
Total Stockholder Equity = 445.7m (last 4 quarters mean from totalStockholderEquity)
RoA = -0.33% (Net Income -3.17m / Total Assets 1.07b)
RoE = -0.71% (Net Income TTM -3.17m / Total Stockholder Equity 445.7m)
RoCE = 3.28% (EBIT 26.5m / Capital Employed (Equity 445.7m + L.T.Debt 363.4m))
RoIC = 1.85% (NOPAT 17.5m / Invested Capital 947.3m)
WACC = 7.03% (E(1.14b)/V(1.59b) * Re(8.42%) + D(452.5m)/V(1.59b) * Rd(5.36%) * (1-Tc(0.34)))
Discount Rate = 8.42% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 65.10 | Cagr: 0.61%
[DCF] Fair Price = unknown (Cash Flow -10.9m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.0 | # QB: 0
Revenue Correlation: 98.54 | Revenue CAGR: 11.73% | SUE: 2.11 | # QB: 1
EPS current Quarter (2026-09-30): EPS=0.07 | Chg30d=-35.10% | Revisions=-44% | Analysts=5
EPS current Year (2026-12-31): EPS=0.40 | Chg30d=-9.89% | Revisions=-25% | GrowthEPS=-36.8% | GrowthRev=+11.1%
EPS next Year (2027-12-31): EPS=0.75 | Chg30d=+3.93% | Revisions=+67% | GrowthEPS=+88.0% | GrowthRev=+10.8%
[Analyst] Revisions Ratio: +6% (up=7, down=6)